We are L-Phenylalanine CAS:63-91-2 manufacturer and supplier in China, Pls send inquiry of to email@example.com of visit www.nbinno.com our official website should you have any interests
An essential amino acid in human. It is widely used as an ingredient in infusion and infant formula.
|Specification||White crystals or crystalline powder, odorless or slightly characteristic odor, slightly bitter taste|
|STORAGE||Controlled room temperature in tight container|
SPECIFICATION AND PROCEDURE
| State of solution
|Not Less Than 97.0%|
|Ammonium (NH4)||Not More Than 0.020%|
|Chloride (Cl)||Not More Than 0.020%|
|Sulfate (SO4)||Not More Than 0.020%|
|Iron (Fe)||Not More Than 10 ppm|
|Heavy metals (Pb)**||Not More Than 10 ppm|
|Arsenic (As2O3)||Not More Than 1 ppm|
|Loss on drying||Not More Than 0.20%|
|Residue on ignition||Not More Than 0.10%|
|Related substances||Not More Than 0.5%|
|Endotoxin*||Less Than 6.0 EU/g|
|Assay (dry basis)||99.0～101.0%|
· * The endotoxin-certified grade will be supplied on request.
· ** FCC grade (Lead : Not More Than 5 mg/kg) will be supplied on request.
· This product meets requirements of residual solvents listed in the current JP, USP and EP.
Related News: In addition, with the increase of environmental protection pressure, nearly one hundred Beijing pharmaceutical companies have gathered in the Bohai Bay, and the raw material drug base in northern China has taken shape.4-Nitroaniline CAS:100-01-6 The upstream industry for the R & D, production and sales of pharmaceutical intermediates is the basic chemical raw material industry, and the downstream industry is the chemical bulk drug and chemical pharmaceutical preparation industry.3,6-dichloro-2-hydroxybenzoic acid CAS:3401-80-7 The upstream industry for the R & D, production and sales of pharmaceutical intermediates is the basic chemical raw material industry, and the downstream industry is the chemical bulk drug and chemical pharmaceutical preparation industry.383-63-1 Catalent, a global leader in clinical supply services, recently announced the launch of its new CTSuccessTM clinical trial planning service, designed to support trial sponsors with earlier, more proactive and robust clinical supply chain planning, and reduce the risk of delays and budget overspend common to clinical trials as they progress.Over the past twelve months, the collaboration team has worked to optimize its processes for making T cells from iPSCs, and has now shown the production of pure T-lymphocytes consisting of both CD8+ and CD4+ T cells having a global gene expression profile that is highly-similar to primary T cells based on a principal component analysis.